Latinovic OS - Search Results

1

Latinovic OS, Reitz M, Heredia A. Latinovic OS, et al. J AIDS HIV Treat. 2019;1(1):1-5. doi: 10.33696/AIDS.1.001. J AIDS HIV Treat. 2019. PMID: 31414081 Free PMC article. No abstract available.

2

Rapamycin reduces CCR5 density levels on CD4 T cells, and this effect results in potentiation of enfuvirtide (T-20) against R5 strains of human immunodeficiency virus type 1 in vitro.

Heredia A, Gilliam B, Latinovic O, Le N, Bamba D, Devico A, Melikyan GB, Gallo RC, Redfield RR. Heredia A, et al. Antimicrob Agents Chemother. 2007 Jul;51(7):2489-96. doi: 10.1128/AAC.01602-06. Epub 2007 May 7. Antimicrob Agents Chemother. 2007. PMID: 17485501 Free PMC article.

3

Reduction of CCR5 with low-dose rapamycin enhances the antiviral activity of vicriviroc against both sensitive and drug-resistant HIV-1.

Heredia A, Latinovic O, Gallo RC, Melikyan G, Reitz M, Le N, Redfield RR. Heredia A, et al. Proc Natl Acad Sci U S A. 2008 Dec 23;105(51):20476-81. doi: 10.1073/pnas.0810843106. Epub 2008 Dec 15. Proc Natl Acad Sci U S A. 2008. PMID: 19075241 Free PMC article.

4

Rapamycin enhances aplaviroc anti-HIV activity: implications for the clinical development of novel CCR5 antagonists.

Latinovic O, Heredia A, Gallo RC, Reitz M, Le N, Redfield RR. Latinovic O, et al. Antiviral Res. 2009 Jul;83(1):86-9. doi: 10.1016/j.antiviral.2009.02.199. Epub 2009 Mar 9. Antiviral Res. 2009. PMID: 19501260

5

Pharmacotherapy of HIV-1 Infection: Focus on CCR5 Antagonist Maraviroc.

Latinovic O, Kuruppu J, Davis C, Le N, Heredia A. Latinovic O, et al. Clin Med Ther. 2009;1:1497-1510. doi: 10.4137/cmt.s2365. Clin Med Ther. 2009. PMID: 19920876 Free PMC article.

6

CCR5 antibodies HGS004 and HGS101 preferentially inhibit drug-bound CCR5 infection and restore drug sensitivity of Maraviroc-resistant HIV-1 in primary cells.

Latinovic O, Reitz M, Le NM, Foulke JS, Fätkenheuer G, Lehmann C, Redfield RR, Heredia A. Latinovic O, et al. Virology. 2011 Mar 1;411(1):32-40. doi: 10.1016/j.virol.2010.12.029. Epub 2011 Jan 12. Virology. 2011. PMID: 21232779 Free PMC article.

7

Synergistic inhibition of R5 HIV-1 by maraviroc and CCR5 antibody HGS004 in primary cells: implications for treatment and prevention.

Latinovic O, Le N, Reitz M, Pal R, DeVico A, Foulke JS, Redfield RR, Heredia A. Latinovic O, et al. AIDS. 2011 Jun 1;25(9):1232-5. doi: 10.1097/QAD.0b013e3283471edb. AIDS. 2011. PMID: 21505306 Free PMC article.

8

Binding of fusion protein FLSC IgG1 to CCR5 is enhanced by CCR5 antagonist Maraviroc.

Latinovic O, Schneider K, Szmacinski H, Lakowicz JR, Heredia A, Redfield RR. Latinovic O, et al. Antiviral Res. 2014 Dec;112:80-90. doi: 10.1016/j.antiviral.2014.10.006. Epub 2014 Oct 24. Antiviral Res. 2014. PMID: 25453341 Free PMC article.

9

Full Length Single Chain Fc Protein (FLSC IgG1) as a Potent Antiviral Therapy Candidate: Implications for In Vivo Studies.

Latinovic OS, Medina-Moreno S, Schneider K, Gohain N, Zapata J, Pazgier M, Reitz M, Bryant J, Redfield RR. Latinovic OS, et al. AIDS Res Hum Retroviruses. 2016 Feb;32(2):178-86. doi: 10.1089/AID.2015.0020. Epub 2015 Jun 22. AIDS Res Hum Retroviruses. 2016. PMID: 26059995 Free PMC article.

10

Synergistic Inhibition of R5 HIV-1 by the Fusion Protein (FLSC) IgG1 Fc and Maraviroc in Primary Cells: Implications for Prevention and Treatment.

Latinovic OS, Zhang J, Tagaya Y, DeVico AL, Fouts TR, Schneider K, Lakowicz JR, Heredia A, Redfield RR. Latinovic OS, et al. Curr HIV Res. 2016;14(1):24-36. doi: 10.2174/1570162x13666150909145150. Curr HIV Res. 2016. PMID: 26354735

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

33 results

Search Page